Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 15/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870140 | 0.79 | TRPV4 (0.44) | TRPV4P2RX7TRPV3 | |
| SCHEMBL22585740 | 0.79 | TRPV4 (0.44) | KCNK3TRPV4P2RX7TRPV3 | |
| SCHEMBL12224816 | 0.79 | TRPV4 (0.44) | KCNK3TRPV4P2RX7TRPV3 | |
| SCHEMBL12757500 | 0.79 | TRPV4 (0.44) | KCNK3TRPV4P2RX7TRPV3 | |
| SCHEMBL2867163 | 0.79 | TRPV4 (0.44) | TRPV4P2RX7TRPV3 | |
| SCHEMBL20350557 | 0.79 | TRPV4 (0.44) | TRPV4P2RX7TRPV3 | |
| SCHEMBL2866235 | 0.79 | TRPV4 (0.44) | TRPV4P2RX7TRPV3 | |
| SCHEMBL14313737 | 0.78 | TRPV4 (0.47) | TRPV4P2RX7TRPV3 | |
| Hydrochloric Acid SCHEMBL20581114 | 0.78 | TRPV4 (0.43) | TRPV4P2RX7TRPV3 | |
| Hydrochloric Acid SCHEMBL20581086 | 0.78 | TRPV4 (0.43) | TRPV4P2RX7TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| CN-110337437-B | Substituted pyrazolopyrimidinones as PDE2 inhibitors | 达特神经科学有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3562828-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110337437-A | Substituted pyrazolopyrimidinone compound as PDE2 inhibitor | 达特神经科学有限公司 | 2019-10-15 | — | — | CN | disclosed |
| WO-2018125810-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125810-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3B | KCNK3 1403/4885TRPV4 1437/4885P2RX7 261/4885 |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | KCNK3 1403/4885TRPV4 1437/4885P2RX7 261/4885 |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, TDP2 | KCNK3 1556/4885TRPV4 1155/4885P2RX7 283/4885 |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | KCNK3 1403/4885TRPV4 1437/4885P2RX7 261/4885 |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | KCNK3 1556/4885TRPV4 1155/4885P2RX7 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.